课题基金 / 基金详情

ANTIDEPRESSANTS IN THE TREATMENT OF ANXIETY DISORDERS

ANTIDEPRESSANTS IN THE TREATMENT OF ANXIETY DISORDERS
抗抑郁药治疗焦虑症
批准号:
3381985
负责人:
MATIG R MAVISSAKALIAN
金额:
$17.45万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1986
资助国家:
美国
项目状态:
已结题
起止时间:
1986-09-01 至 1990-07-31

项目摘要

项目成果

MATIG R MAVISSAKALIAN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The study consists of a double-blind, randomized, placebo- controlled prospective one year maintenance study of imipramine in panic disorder with agoraphobia patients who have shown good and stable response to open treatment with imipramine at the fixed weight adjusted dosage of 2.25 mg/kg/day and exposure instruction, in the preceding six months of active treatment. The first 90 patients to show marked response at both the four months and six months assessments of active treatment will be randomly assigned to one year maintenance, either on the full dose (2.25 mg/kg/day), half that dose (1.125 mg/kg/day) or placebo with planned assessments every two months. Assessments will include demographic and clinical information and a comprehensive battery of clinician and patient ratings of the three most salient major symptom domains of the disorder: panic, phobia and dysphoria/depression, as well as operationalized and clinically relevant definitions of dose response and relapse. The specific aim of the study is to determine the extent to which long-term improvement and response in panic disorder agoraphobia depend on the continued administration of imipramine, the maintenance dose and its bioavailability. In view of the chronic and fluctuating course of this disorder and the increasing numbers of patients who are effectively treated with imipramine or similar drugs, the results of the study should have important practical/clinical implications for the long-term management of panic disorder/agoraphobic patients with pharmacological agents i.e., relapse and duration to relapse upon discontinuation of imipramine, risk-benefit ratio of maintenance treatment and compliance. In addition, the study extends our programmatic research in the characterization of imipramine's short-term effects in panic disorder and agoraphobia. Thus, the delineation of different dose/plasm concentration response patterns during the active and long-term maintenance treatment phases would suggest that mechanisms which mediate improvement in this disorder may be different from those which maintain improvement.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ANTIDEPRESSANTS IN ANXIETY DISORDERS--DISCONTINUATION/MAINTENANCE W/ IMIPRAMINE
  • 批准号:
    6305411
  • 项目类别:
  • 资助金额:
    $1.92万
  • 财政年份:
    1999
  • 负责人:
    MATIG R MAVISSAKALIAN
  • 依托单位:
ANTIDEPRESSANTS IN ANXIETY DISORDERS--DISCONTINUATION/MAINTENANCE W/ IMIPRAMINE
  • 批准号:
    6115331
  • 项目类别:
  • 资助金额:
    $1.92万
  • 财政年份:
    1998
  • 负责人:
    MATIG R MAVISSAKALIAN
  • 依托单位:
ANTIDEPRESSANTS IN ANXIETY DISORDERS--DISCONTINUATION/MAINTENANCE W/ IMIPRAMINE
  • 批准号:
    6276565
  • 项目类别:
  • 资助金额:
    $1.83万
  • 财政年份:
    1997
  • 负责人:
    MATIG R MAVISSAKALIAN
  • 依托单位:
ANTIDEPRESSANTS IN THE TREATMENT OF ANXIETY DISORDERS
  • 批准号:
    2245524
  • 项目类别:
  • 资助金额:
    $23.61万
  • 财政年份:
    1986
  • 负责人:
    MATIG R MAVISSAKALIAN
  • 依托单位:
海外基金